Oncology focus – Developing the leading pipeline of drugs targeting
the PI3K/mTOR pathway
Accomplished leadership team – Experts in kinase drug discovery
and oncology drug development
Well-capitalized – Raised $41M from
world-class investors
Significant momentum – First program (TORC1/2) entered human clinical study 18 months after discovery of hit
Creative deal-making – $489M partnership for PI3Kδ/γ announced in July 2010
Robust pipeline – Three clinical-stage
programs directed against TORC1/2, PI3Kα and PI3Kδ/γ